AMED

Amedisys Inc

Add to Watchlist

Advanced Chart

97.940

+0.11(0.112%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

98.310

Open

98.310

VWAP

97.90

Vol

417.52K

Mkt Cap

3.21B

Low

97.450

Amount

40.87M

EV/EBITDA(TTM)

12.01

Total Shares

32.68M

3.35B

EV/OCF(TTM)

14.90

P/S(TTM)

1.36

Amedisys, Inc. is a healthcare services company. It provides in-home healthcare and related services to the chronic, co-morbid and aging American population. Its segments include home health, hospice and high acuity care. Its home health segment delivers a range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Its nurses administer medications, care for wounds, monitor vital signs and provide a range of other nursing services. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility care to patients in their homes. It owns and operates 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers and eight admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

611.71M

+3.47%

1.334

+1.1%

616.31M

+4.87%

1.119

+11.86%

628.05M

+5.02%

1.100

+14.58%

Estimates Revision

The market is revising Downward the revenue expectations for Amedisys, Inc. (AMED) for FY2025, with the revenue forecasts being adjusted by -0.18% over the past three months. During the same period, the stock price has changed by 3.43%.

Revenue Estimates for FY2025

Revise Downward

-0.18%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.28%

In Past 3 Month

Stock Price

Go Up

+3.43%

In Past 3 Month

6 Analyst Rating

2.87% Upside

Wall Street analysts forecast AMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMED is 100.75 USD with a low forecast of 100.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

5 Hold

0 Sell

Hold

2.87% Upside

Current: 97.940

Low

100.00

Averages

100.75

High

101.00

2.87% Upside

Current: 97.940

Low

100.00

Averages

100.75

High

101.00

RBC Capital

Ben Hendrix

Buy

Reiterates

$100

2025-04-16

Reason

RBC Capital

Ben Hendrix

Price Target

$100

2025-04-16

Reiterates

Buy

Reason

Stephens & Co.

Scott Fidel

Hold

Reiterates

$101

2025-03-04

Reason

Stephens & Co.

Scott Fidel

Price Target

$101

2025-03-04

Reiterates

Hold

Reason

Stephens & Co.

Raj Kumar

Hold

Reiterates

$101

2025-02-12

Reason

Stephens & Co.

Raj Kumar

Price Target

$101

2025-02-12

Reiterates

Hold

Reason

Deutsche Bank

Justin Bowers

Strong Buy

Hold

Downgrades

$101

2024-07-31

Reason

Deutsche Bank

Justin Bowers

Price Target

$101

2024-07-31

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amedisys Inc (AMED.O) is 20.19, compared to its 5-year average forward P/E of 26.62. For a more detailed relative valuation and DCF analysis to assess Amedisys Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

26.62

Current PE

20.19

Overvalued PE

36.52

Undervalued PE

16.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

17.99

Current EV/EBITDA

13.16

Overvalued EV/EBITDA

24.49

Undervalued EV/EBITDA

11.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.96

Current PS

1.29

Overvalued PS

2.96

Undervalued PS

0.96

Financials

Annual

Quarterly

FY2025Q1

YoY :

+4.09%

594.78M

Total Revenue

FY2025Q1

YoY :

+15.00%

60.13M

Operating Profit

FY2025Q1

YoY :

+323.61%

61.82M

Net Income after Tax

FY2025Q1

YoY :

+318.18%

1.84

EPS - Diluted

FY2025Q1

YoY :

-45.91%

-5.10M

Free Cash Flow

FY2025Q1

YoY :

+0.26%

43.09

Gross Profit Margin - %

FY2025Q1

YoY :

+128.78%

9.22

FCF Margin - %

FY2025Q1

YoY :

+307.45%

10.39

Net Margin - %

FY2025Q1

YoY :

-433.50%

6.57

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

35.9K

USD

3-6

Months

187.8K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 103.17% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

929.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

269.0K

Volume

Months

6-9

132.4K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

35.9K

USD

3-6

Months

187.8K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMED News & Events

Events Timeline

2025-07-01 (ET)

2025-07-01

09:52:23

Home health stocks under pressure following proposed rate cuts

2025-04-23 (ET)

2025-04-23

16:53:19

Amedisys reports Q1 adjusted EPS $1.25, consensus $1.11

2025-02-26 (ET)

2025-02-26

16:40:15

Amedisys reports Q4 adjusted EPS 96c, consensus $1.06

News

7.0

07-10Reuters

Trump's antitrust enforcers 'get out of the way' of multibillion-dollar deals

8.0

07-01Benzinga

Home Health Braces For Potential $1 Billion Cut In Medicare Payments

8.0

07-01SeekingAlpha

Proposed Medicare payment cut for home health could scuttle UnitedHealth/Amedisys deal

People Also Watch

BNL

Broadstone Net Lease Inc

Genworth Financial Inc

Brighthouse Financial Inc

Corporacion America Airports SA

Marriott Vacations Worldwide Corp

84.190

USD

+2.23%

FAQ

What is Amedisys Inc (AMED) stock price today?

The current price of AMED is 97.94 USD — it has increased 0.11 % in the last trading day.

AMED

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AMED News & Events

Events Timeline

News

People Also Watch

FAQ

What is Amedisys Inc (AMED) stock price today?

What is Amedisys Inc (AMED)'s business?

What is the price predicton of AMED Stock?

What is Amedisys Inc (AMED)'s revenue for the last quarter?

What is Amedisys Inc (AMED)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Amedisys Inc (AMED)'s fundamentals?

How many employees does Amedisys Inc (AMED). have?

What is Amedisys Inc (AMED) market cap?